The Chemokine CXCL13 (BCA-1) Inhibits FGF-2 Effects on Endothelial Cells

doi:10.1006/bbrc.2001.5924

Biochemical and Biophysical Research Communications

Volume 289, Issue 1, 23 November 2001, Pages 19-24

https://doi.org/10.1006/bbrc.2001.5924 Get rights and content

Abstract

Several chemokines, belonging to both the CXC and CC classes, act as positive or negative regulators of angiogenesis. We sought to investigate the role of CXCL13, B cell-attracting chemokine 1 (BCA-1), also known as B-lymphocyte chemoattractant (BLC), on endothelial cell functions. We tested the effect of CXCL13 on HUVEC chemotaxis and proliferation in the presence of fibroblast growth factor (FGF)-2 and found that such chemokine inhibits FGF-2-induced functions, while is not active by itself. To test whether other FGF-2-mediated biological activities may be affected, we evaluated the ability of CXCL13 to rescue HUVEC from starvation-induced apoptosis, as FGF-2 is a survival factor for endothelial cells, and found that CXCL13 partially inhibits such rescue. Multiple mechanisms may be responsible for these biological activities as CXCL13 displaces FGF-2 binding to endothelial cells, inhibits FGF-2 homodimerization, and induces the formation of CXCL13–FGF-2 heterodimers. Our data suggest that CXCL13 may modulate angiogenesis by interfering with FGF-2 activity.

References (32)

R.M. Strieter et al.
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
J. Biol. Chem.
(1995)
S. Gengrinovitch et al.
Platelet factor-4 inhibits the mitogenic activity of VEGF₁₂₁ and VEGF₁₆₅ using several concurrent mechanisms
J. Biol. Chem.
(1995)
R. Salcedo et al.
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha
Am. J. Pathol.
(1999)
C. Perollet et al.
Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization
Blood
(1998)
G. Gentilini et al.
Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1)
Blood
(1999)
S.A. Luther et al.
BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis
Immunity
(2000)
C.H. Jenh et al.
Human b cell-attracting chemokine 1 (bca-1; cxcl13) is an agonist for the human cxcr3 receptor
Cytokine
(2001)
M.J. Endres et al.
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
Cell
(1996)
S.K. Gupta et al.
Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines
J. Biol. Chem.
(1998)
G. Bernardini et al.
I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo
Blood
(2000)

A.C. Rapraeger et al.

Regulation by heparan sulfate in fibroblast growth factor signaling

Methods Enzymol.

(1994)

A. Yayon et al.

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

Cell

(1991)

S. Matsuda et al.

Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain

Brain Res.

(1990)

D.M. Pataky et al.

Fibroblast growth factor treatment produces differential effects on survival and neurite outgrowth from identified bulbospinal neurons in vitro

Exp. Neurol.

(2000)

T.A. Springer

Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm

Cell

(1994)

Cited by (37)

Far beyond anti-angiogenesis: Benefits for anti-basicFGF therapy in cancer
2022, Biochimica et Biophysica Acta - Molecular Cell Research
Basic FGF (bFGF) was discovered as a typical inducer of angiogenesis and has already been studied for 3 decades. Recent evidence indicates that bFGF plays different roles and controls signaling pathways that participate in the hallmarks of cancer, underscoring bFGF an appealing target for anti-cancer therapy. However, the early clinical trials designed to block bFGF signaling showed safety without satisfiable benefits for cancer patients. In this review, we firstly discuss bFGF's canonical signaling pathways and later review newly identified bFGF's functions that contribute to the cancer hallmarks besides its typical role in angiogenesis. After, we summarize the role of bFGF as a therapeutic target in response to different cancer therapies including radiotherapy, chemotherapy, targeted therapy, immunotherapy, and highlight the difficulties we must solve regarding the design of drugs targeting specifically bFGF. We also emphasize the need, especially for natural bFGF traps, to deepen their molecular mechanisms of action considering the specific context of cancer with different FGFR status, as well as the urgence of stratifying patients for both anti-bFGF first line and second line anti-cancer therapy. Finally, a perspective on potential feed-forward oncogenic signaling pathways mediated by bFGF is made. We discuss the importance of developing additional robust biomarkers to select patients who will benefit from bFGF-targeted therapy, as well as the rationale of developing combinatory therapies targeting either bFGF and/or its intracellular (co)effectors. This would ultimately provide novel therapeutic strategies to fight cancer.
The expression and role of CXC chemokines in colorectal cancer
2011, Cytokine and Growth Factor Reviews
Citation Excerpt :
CXCR3 binding ELR− CXC chemokines have angiostatic activities and include platelet factor-4 (PF-4)/CXCL4, platelet factor-4 variant (PF-4var)/CXCL4L1, monokine induced by interferon-γ (Mig)/CXCL9, interferon-γ inducible protein-10 (IP-10)/CXCL10 and interferon-inducible T cell alpha chemoattractant (I-TAC)/CXCL11 [10,12]. Also B cell-attracting chemokine-1 (BCA-1)/CXCL13, which binds CXCR5, is an angiostatic ELR− CXC chemokine [22]. The first evidence that non-neoplastic cells might influence tumor formation and growth came from the field of inflammation.
Cancer is a life-threatening disease world-wide and colorectal cancer is the second common cause of cancer mortality. The interaction between tumor cells and stromal cells plays a crucial role in tumor initiation and progression and is partially mediated by chemokines. Chemokines predominantly participate in the chemoattraction of leukocytes to inflammatory sites. Nowadays, it is clear that CXC chemokines and their receptors (CXCR) may also modulate tumor behavior by several important mechanisms: regulation of angiogenesis, activation of a tumor-specific immune response by attracting leukocytes, stimulation of tumor cell proliferation and metastasis. Here, we review the expression and complex roles of CXC chemokines (CXCL1 to CXCL16) and their receptors (CXCR1 to CXCR6) in colorectal cancer. Overall, increased expression levels of CXC chemokines correlate with poor prognosis.
The role of CXC chemokines and their receptors in cancer
2008, Cancer Letters
Chemokines, or chemotactic cytokines, and their receptors have been discovered as essential and selective mediators in leukocyte migration to inflammatory sites and to secondary lymphoid organs. Besides their functions in the immune system, they also play a critical role in tumor initiation, promotion and progression. There are four subgroups of chemokines: CXC, CC, CX₃C, and C chemokine ligands. The CXC or α subgroup is further subdivided in the ELR⁺ and ELR⁻ chemokines. Members that contain the ELR motif bind to CXC chemokine receptor 2 (CXCR2) and are angiogenic. In contrast, most of the CXC chemokines without ELR motif bind to CXCR3 and are angiostatic. An exception is the angiogenic ELR⁻CXC chemokine stromal cell-derived factor-1 (CXCL12/SDF-1), which binds to CXCR4 and CXCR7 and is implicated in tumor metastasis. This review is focusing on the role of CXC chemokines and their receptors in tumorigenesis, including angiogenesis, attraction of leukocytes to tumor sites and induction of tumor cell migration and homing in metastatic sites. Finally, their therapeutic use in cancer treatment is discussed.
The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML)
2023, Cancers
Vascular reconstruction of the decellularized biomatrix for whole-organ engineering—a critical perspective and future strategies
2023, Frontiers in Bioengineering and Biotechnology
NEWCASTLE DISEASE VIRUS SUPPRESSES ANGIOGENESIS IN MAMMARY ADENOCARCINOMA MODELS
2022, Bulgarian Journal of Veterinary Medicine

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata–IDI, 00167, Via Monti di Creta 104, Rome, Italy. Fax: 39-06-66462430. E-mail: [email protected].

View full text

Regular ArticleThe Chemokine CXCL13 (BCA-1) Inhibits FGF-2 Effects on Endothelial Cells

Abstract

J. Biol. Chem.

J. Biol. Chem.

Am. J. Pathol.

Blood

Blood

Immunity

Cytokine

Cell

J. Biol. Chem.

Blood

Methods Enzymol.

Cell

Brain Res.

Exp. Neurol.

Cell

Regular Article
The Chemokine CXCL13 (BCA-1) Inhibits FGF-2 Effects on Endothelial Cells